Announced Tue, 14 Apr · 13:18 IST
Jenburkt Pharmaceuticals Confirms 'Not a Large Corporate' Status for FY2026
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.0%1-day move
₹1030.00
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-1.0+0.7+2.3+3.1+2.9+2.0+13.6+16.5+13.1+6.1
Up moveDown movePending
AI summary
Jenburkt Pharmaceuticals has confirmed to BSE, under SEBI's August 10, 2021 circular, that it does not qualify as a 'large corporate' for the financial year ended March 31, 2026. This means the company falls below the SEBI threshold that classifies firms as large corporates based on outstanding borrowings, exempting it from the extra borrowing and disclosure requirements meant for larger entities.
Likely market impact
Neutral regulatory compliance filing. No material impact on shareholders; company is exempt from additional large-corporate requirements.